1Edgell T, Martin-Roussety G, Barker G, et al. Phase II bio- marker trial of a multimarker diagnostic for ovarian cancer [J]. J Cancer Res Clin Oncol,2010,136(7):1079-1088.
2Kulasingam V, Pavlou MP, Diamandis EP. Integrating high-throughput technologies in the quest for effective bi- omarkers for ovarian cancer[ J]. Nat Rev Cancer,2010, 10(5 ) :371-378.
3Lu R ,Sun M, Feng J, et al. Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancer [ J ]. BMC cancer, 2011, 270( 11 ) :234-242.
4Kothandaraman N, Bajic VB, Brendan PN, et al. E2F5 sta- tus significantly improves malignancy diagnosis of epitheli- al ovarian cancer [ J ]. BMC Cancer, 2010,64 ( 10 ) : 336- 342.
5Andersen MR,Goff BA,Lowe KA,et al. Use of a Symptom Index,CA125, and HE 4 to predict ovarian cancer [ J ]. Gynecol Oncol, 2010,116 ( 3 ) :378-383.
6Nobbenhuis MA, Bancroft E, Moskovic E, et al. Screening for ovarian cancer in women with varying levels of risk, u- sing annual tests, results in high recall for repeat screening tests [ J ]. Hered Cancer Clin Pract,2011,9 ( 11 ) : 1-6.
7Gang He, Holcroft CA, Beauchamp MC, et al. Combination of serum biomarkers to differentiate malignant from benign ovarian tumours [ J ] Obstet Gynaecol Can, 2012,34 ( 6 ) : 567-574.
8Nakamura K, Hongo A, Kodama J, et al. The pretreatment of maximum standardized uptake values (SUVmax) of the primary tumor is predictor for poor prognosis for patients with epithelial ovarian canner[ J]. Acta Medica Okayama, 2012,66( 1 ) :53-60.
9Kobayashi H,Ooi H,Yamada Y,et al. Serum CA125 level before the development of ovarian cancer[ J ]. Int J Gynae- col Obstet ,2007,99 (2) :95-99.
6O'Farrell PH. 1975. High resolutlon two dimensional electrophoresis of proteins. Journal of Biological Chemisty, 250(10) : 4007 -4021.
7Scheler C, Lamer S, Pan Z, et al. 1998. Peptide mass fingerprint sequence coverage from differently stained proteins on two - dimensional electrophoresis patterns by matrix assisted lasered esorption/ioniza- tion - mass spectrometry ( MALDI - MS) Electrophoresis, 19(3) : 918- 927.
8Chaurand P, Fouchecourt S, DaGue BB, et al. Profiling and imaging proteins in the mouse epididymis by imaging mass spectrometry. Proteomics, 3 ( 11 ) : 2221 - 2239.
9MacBeath G,Schreiber SL. 2000. Printing proteins as microarray for high - throughput function determination Science, 289 (5485) : 1760 - 1763.
10Davies H, Lomas L, Austen B 1999. Profiling of amyloid beta peptide variants using SELDI protein chip arrays. Biotechniqnes, 27 ( 6 ) : 1258-1270.
5Sjvall K, Nilsson B, Einhom N. The significance of serum CA125 elevation in malignant and nonmalignant diseases[J ]. Gynecologic oncology, 2002, 85(1) : 175.
6Burger A M, Seth A K. The ubiquitin mediated protein degradation pathway in cancer: therapeutic implications [J ].European journal of cancer, 2004, 40(15) : 2217.
7Kirchhoff C, Habben I, Ivell R, et al. A major human epi- didymis specific cDNA encodes a protein with sequence ho- mology to extracellular proteinase inhibitors [ J ]. Biology of reproduction, 1991, 45(2): 350.
8Moore R G, McMeekin D S, Brown A K, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass[J ]. Gynecologic oncology, 2009, 112 ( 1 ) : 40.
9Moore R G, Brown A K, Miller M C, et al. The use of mul tiple novel tumor biomarkers for the detection of ovarian car cinoma in patients with a pelvic mass[J ]. Gynecologic oncol ogy, 2008, 108(2): 402.
